What Is Spero Therapeutics, Inc. (SPRO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Spero Therapeutics, Inc.'s intrinsic value is estimated at a composite $1.71, showing conflicting signals at the current price of $1.70. While the average implied return is +0.5%, model disagreement is elevated with a gap of +274.7% between the most bullish and bearish estimates. The most optimistic model, RCMH-DCF, places fair value at $4.71 (+176.8%), while ML-RIV — the most conservative — estimates $0.03 (-98.0%). This +274.7% gap reflects genuine analytical uncertainty about Spero Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About SPRO?
10 of 13 models are currently active for SPRO. Of these, 4 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates SPRO's intrinsic value at $1.09, implying -35.7% downside from the current price. See which stocks rank higher →
How Does SPRO Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SPRO ranks #106 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Spero Therapeutics, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is SPRO a Value Trap?
CirclFi's Value Trap algorithm assigns SPRO a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Spero Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Spero Therapeutics, Inc. scores 6.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +274.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SPRO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SPRO's 10 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad